Jean‐Michel Vernier

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

Elena Ardini, Maria Menichincheri, Patrizia Banfi et al. · Molecular Cancer Therapeutics · 2016 · 308 citations · Full text

RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer

Cory Iverson, Gary Larson, Chon Lai et al. · Cancer Research · 2009 · 182 citations · Full text

Chemoprevention Strategy, Cell Proliferation, Tumor Biology +20

Pharmacological Characterization and Identification of Amino Acids Involved in the Positive Modulation of Metabotropic Glutamate Receptor Subtype 2

Hervé Schaffhauser, Blake A. Rowe, Sylvia Morales et al. · Molecular Pharmacology · 2003 · 158 citations

Group II mGlu Receptor Activation Suppresses Norepinephrine Release in the Ventral Hippocampus and Locomotor Responses to Acute Ketamine Challenge

Daniel S. Lorrain, Hervé Schaffhauser, Una C. Campbell et al. · Neuropsychopharmacology · 2003 · 94 citations · Full text

Locomotor Responses, Neurophysiology, Medicine +11

(<i>S</i>)-(−)-5-Ethynyl-3-(1-methyl-2-pyrroli- dinyl)pyridine Maleate (SIB-1508Y):  A Novel Anti-Parkinsonian Agent with Selectivity for Neuronal Nicotinic Acetylcholine Receptors

Nicholas D. P. Cosford, Leo Bleicher, Audrey Herbaut et al. · Journal of Medicinal Chemistry · 1996 · 92 citations · Full text

Synaptic Transmission, Neurotransmitter, Altmetric Attention Score +20